STOCK TITAN

Stemtech Expands Into The $303 Billion Pet Health Care Market With Launch Of Stempets(TM)

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Stemtech (OTCQB:STEK) has launched StemPets™, a new product line for the $303 billion pet health care market. This natural stemceutical product, designed for dogs, cats, and other pets, aims to provide health benefits similar to Stemtech's human products. StemPets contains cashew nut-shell oil (Anacardic Acid) and a special stem cell nutrition formula to support organ repair, immune system, and joint health.

The product is non-GMO, free from artificial additives, and increases circulating stem cells in pets. Stemtech has secured an exclusive distribution agreement for StemPets. This expansion is expected to attract younger distributors, particularly Gen X individuals under 40. Stemtech has a history of delivering over $600 million worth of nutraceutical products with a return rate of less than 2%.

Stemtech (OTCQB:STEK) ha lanciato StemPets™, una nuova linea di prodotti per il mercato della salute degli animali domestici da 303 miliardi di dollari. Questo prodotto naturale stemceutico, progettato per cani, gatti e altri animali, mira a fornire benefici per la salute simili a quelli dei prodotti umani di Stemtech. StemPets contiene olio di guscio di anacardo (Acido Anacardico) e una speciale formula nutritiva a base di cellule staminali per supportare la riparazione degli organi, il sistema immunitario e la salute delle articolazioni.

Il prodotto è non-OGM, privo di additivi artificiali e aumenta le cellule staminali circolanti negli animali domestici. Stemtech ha assicurato un accordo di distribuzione esclusivo per StemPets. Si prevede che questa espansione attragga distributori più giovani, in particolare individui della Generazione X sotto i 40 anni. Stemtech ha una storia di fornitura di oltre 600 milioni di dollari di prodotti nutraceutici con un tasso di ritorno di meno del 2%.

Stemtech (OTCQB:STEK) ha lanzado StemPets™, una nueva línea de productos para el mercado de cuidado de la salud de mascotas de 303 mil millones de dólares. Este producto natural de stemceuticals, diseñado para perros, gatos y otras mascotas, tiene como objetivo proporcionar beneficios para la salud similares a los productos humanos de Stemtech. StemPets contiene aceite de cáscara de anacardo (Ácido Anacárdico) y una fórmula especial de nutrición celular para apoyar la reparación de órganos, el sistema inmunológico y la salud de las articulaciones.

El producto es no transgénico, libre de aditivos artificiales y aumenta las células madre circulantes en las mascotas. Stemtech ha asegurado un acuerdo de distribución exclusivo para StemPets. Se espera que esta expansión atraiga a distribuidores más jóvenes, particularmente a personas de la Generación X menores de 40 años. Stemtech tiene un historial de entrega de más de 600 millones de dólares en productos nutracéuticos con una tasa de retorno de menos del 2%.

스템텍 (OTCQB:STEK)스템펫 (StemPets™), 새로운 반려동물 건강 관리 시장을 위한 3030억 달러 규모의 제품 라인을 출시했습니다. 이 자연 유래 줄기세포 제품은 개, 고양이 및 기타 반려동물을 위해 설계되어, 스템텍의 인간 제품과 유사한 건강상 혜택을 제공하는 것을 목표로 합니다. 스템펫에는 캐슈너트 껍질 오일 (아나카르딕산)과 장기 회복, 면역체계 및 관절 건강을 지원하기 위한 특별한 줄기세포 영양 포뮬러가 포함되어 있습니다.

이 제품은 비유전자 변형이며, 인공 첨가물이 없고, 반려동물의 순환 줄기세포를 증가시킵니다. 스템텍은 스템펫에 대해 독점 배급 계약을 체결했습니다. 이번 확장은 특히 40세 이하의 X세대 유통업체를 유치할 것으로 예상됩니다. 스템텍은 6억 달러 이상의 영양 제품을 제공하며, 반품률은 2% 이하입니다.

Stemtech (OTCQB:STEK) a lancé StemPets™, une nouvelle gamme de produits pour le marché des soins de santé pour animaux de compagnie de 303 milliards de dollars. Ce produit naturel de stemcéutiques, conçu pour les chiens, les chats et d'autres animaux de compagnie, vise à fournir des bienfaits pour la santé similaires à ceux des produits humains de Stemtech. StemPets contient huile de coque de noix de cajou (Acide Anacardique) et une formule spéciale de nutrition par cellules souches pour soutenir la réparation des organes, le système immunitaire et la santé des articulations.

Le produit est sans OGM, exempt d'additifs artificiels et augmente les cellules souches circulantes chez les animaux de compagnie. Stemtech a sécurisé un accord de distribution exclusif pour StemPets. Cette expansion devrait attirer des distributeurs plus jeunes, en particulier les membres de la génération X de moins de 40 ans. Stemtech a une histoire de livraison de plus de 600 millions de dollars en produits nutraceutiques avec un taux de retour de moins de 2%.

Stemtech (OTCQB:STEK) hat StemPets™ eingeführt, eine neue Produktreihe für den 303 Milliarden Dollar schweren Markt für Haustiergesundheit. Dieses natürliche Stammzellenprodukt, das für Hunde, Katzen und andere Haustiere entwickelt wurde, zielt darauf ab, gesundheitliche Vorteile ähnlich wie die menschlichen Produkte von Stemtech zu bieten. StemPets enthält Anacardium -Nuss-Schalenöl (Anacardinsäure) und eine spezielle Stammzellernährungsformel zur Unterstützung der Organreparatur, des Immunsystems und der Gelenkgesundheit.

Das Produkt ist nicht gentechnisch verändert, frei von künstlichen Zusatzstoffen und erhöht die zirkulierenden Stammzellen bei Haustieren. Stemtech hat einen exklusiven Vertriebsvertrag für StemPets gesichert. Er wird erwartet, dass diese Expansion jüngere Vertriebsmitarbeiter anzieht, insbesondere Personen der Generation X unter 40 Jahren. Stemtech hat eine Geschichte von über 600 Millionen Dollar wertvoller nutraceutical Produkte mit einer Rücksendungsquote von weniger als 2%.

Positive
  • Expansion into the $303 billion pet health care market
  • Launch of StemPets™, a new product line for pets
  • Exclusive distribution agreement secured for StemPets
  • Potential to attract younger distributors (Gen X under 40)
  • History of delivering over $600 million worth of nutraceutical products
  • Low return rate of less than 2% on existing products
Negative
  • None.

NAPLES, FL / ACCESSWIRE / August 22, 2024 / Stemtech Corporation (OTCQB;STEK), a leader in the development and distribution of stemceutical™ products for humans offered since 2005, is proud to announce an exciting new product line into the pet health care industry with the launch of "StemPets™." This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market.

Recognizing the profound love humans hold for their pets and the significant expenses they incur to keep them healthy, Stemtech has developed StemPets. This natural stemceutical product promises to offer amazing health benefits to pets as our human products have provided for nearly two decades.

"We are thrilled to introduce StemPets to the market," said Charles S. Arnold", Chairman & CEO of Stemtech. He goes on to say that "pet owners go to great lengths to ensure the well-being of their animals, and StemPets offers a natural solution that supports their health. Our product is not only beneficial for pet health, but is also appealing to them, as animals find the natural flavor pleasant without the need for artificial flavoring. My eight-year-old dog Plato has more energy and vitality since taking StemPets."

John W. Meyer, President & COO states "the new StemPets product with the active ingredient being cashew nut-shell oil, or Anacardic Acid, (an ingredient listed in the AAFCO - Association of American Feed Control Officials) combined with our special ingredients for stem cell nutrition formula create tremendous health benefits for our furry friends. This product will support the body's ability to repair and regenerate organs, support the immune system and improves joint health. Further, it is non-GMO, containing no salt, artificial colors, gluten, flavors or sweeteners, soy or wheat. It increases the number of circulating stem cells, just like our other great products for humans. StemPets supports anti-aging and will revitalize pets, keeping them healthy with more longevity".

Global Market Enterprise LTD, the owner of proprietary technology, represented by Mr. Steve Tollman, and the provider of the uniquely extracted and processed, naturally occurring Anacardic Acid, Cardol and Cardanol, in Cashew Nut shells says "the Stemtech formula containing our proprietary ingredient concentrated Anacardic Acid, Cardol (CD) and Cardanol (CDN) that is further processed to resist the stomach acid of dogs and cats to be efficiently and effectively absorbed in the intestines, key to delivering the antioxidant, anti-inflammation supplement to improve gut health in general, resulting in better nutrition absorption and animal calmness. Each grain of product is coated with a special process so that the stomach acid does not break down the long chain of fatty acid combination so it can have a maximum impact in the intestines".

Stemtech has negotiated an exclusive distribution agreement for StemPets, ensuring that this novel product will be available through our established channels. Over the past year, we have tested StemPets with a variety of pet owners, receiving overwhelmingly positive feedback regarding its natural taste and health benefits.

This expansion into the pet health care industry also presents a significant opportunity for younger distributors of our products, including Gen X individuals under 40 who may not yet prioritize human stem cell health but are enthusiastic about superior health products for their pets. Stemtech's dedication to scientific innovation and health continues with the introduction of StemPets, marking a new chapter in our mission to improve lives, both human and animal.

Since its inception, Stemtech has delivered over $600 million worth of nutraceutical products to consumers, benefiting countless individuals with our pioneering stem cell nutrition technology. Our patented products, known for their ability to naturally stimulate the release of the body's own stem cells, have had less than a 2% return rate, even with a 100% money-back guarantee. These products help slow down the aging process and aid in natural body repair, particularly crucial as the release of stem cells diminishes as we get older.

ABOUT STEMTECH

Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTC: STEK) and has expanded business opportunities for its Independent Business Partners (IBPs), who may earn incomes by sharing Stemtech products. Stemtech is well positioned as the pioneer in stem cell nutrition, oral and skin care products, to increase sales in the wellness industry.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July16, 2024. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

Investor Relations:

Gabriel Rodriguez
Email: erelationsgroup@gmail.com
Phone: +1 623-261-9046

Stemtech Corporation
Phone: +1 954-715-6000 ext 1040
Email: invrel@stemtech.com

SOURCE: Stemtech Corporation



View the original press release on accesswire.com

FAQ

What is Stemtech's new product for the pet health care market called?

Stemtech's new product for the pet health care market is called StemPets™.

What is the main active ingredient in StemPets (STEK)?

The main active ingredient in StemPets is cashew nut-shell oil, also known as Anacardic Acid.

How large is the pet health care market that Stemtech (STEK) is entering?

Stemtech is entering the $303 billion pet health care market with its new product, StemPets™.

What are the key benefits of StemPets for pets?

StemPets supports organ repair and regeneration, improves the immune system, enhances joint health, and promotes anti-aging in pets.

Is StemPets (STEK) available for all types of pets?

StemPets is designed for dogs, cats, and other beloved pets, offering health benefits similar to Stemtech's human products.

STEMTECH CORP

OTC:STEK

STEK Rankings

STEK Latest News

STEK Stock Data

6.74M
92.19M
31.59%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Naples